Patents by Inventor Susan F. Murray
Susan F. Murray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240254492Abstract: Provided herein are specific inhibitors, compositions, methods and uses for reducing expression of COASY in a cell or individual. Such specific inhibitors, compositions, and methods are useful to treat a liver disease or disorder, including but not limited to NASH, in a subject.Type: ApplicationFiled: May 19, 2022Publication date: August 1, 2024Inventors: Omri GOTTESMAN, Shannon BRUSE, Brian CAJES, David JAKUBOSKY, Sarah KLEINSTEIN, John VEKICH, Richard LEE, Susan F. MURRAY
-
Publication number: 20230310483Abstract: Methods, compounds, and compositions useful for inhibiting HSD17B13 expression are provided. Such compounds, compositions, and methods are useful for treating, preventing, or ameliorating a disease associated with HSD 17B 13.Type: ApplicationFiled: June 14, 2023Publication date: October 5, 2023Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Susan F. Murray
-
Patent number: 11744846Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.Type: GrantFiled: May 21, 2021Date of Patent: September 5, 2023Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
-
Publication number: 20220273691Abstract: Methods, compounds, and compositions useful for inhibiting HSD expression are provided. Such compounds, compositions, and methods are useful for treating, preventing, or ameliorating a disease associated with HSD 17B 13.Type: ApplicationFiled: December 20, 2019Publication date: September 1, 2022Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Susan F. MURRAY
-
Publication number: 20210346421Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.Type: ApplicationFiled: May 21, 2021Publication date: November 11, 2021Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
-
Patent number: 11013758Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.Type: GrantFiled: August 28, 2019Date of Patent: May 25, 2021Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
-
Publication number: 20210000906Abstract: Provided herein are methods, compounds, and compositions for reducing expression of HSD17B13 in a cell or individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a liver disease, metabolic disease, or cardiovascular disease or disorder, including but not limited to NASH, in an individual.Type: ApplicationFiled: March 21, 2019Publication date: January 7, 2021Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan F. Murray, Jiangwei Zhang, Huynh-Hoa Bui
-
Publication number: 20200392510Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.Type: ApplicationFiled: January 15, 2019Publication date: December 17, 2020Inventors: Susan M. FREIER, Huynh-Hoa BUI, Susan F. MURRAY, Brett P. MONIA, Shuling GUO
-
Publication number: 20200069722Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.Type: ApplicationFiled: August 28, 2019Publication date: March 5, 2020Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
-
Patent number: 10577607Abstract: Provided herein are methods, compounds, and compositions for reducing expression of DYRKIB in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease or disorder in an individual in need.Type: GrantFiled: March 16, 2017Date of Patent: March 3, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Shuling Guo, Susan F. Murray
-
Patent number: 10426789Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.Type: GrantFiled: February 26, 2016Date of Patent: October 1, 2019Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
-
Publication number: 20190241896Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.Type: ApplicationFiled: January 15, 2019Publication date: August 8, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan M. Freier, Huynh-Hoa Bui, Susan F. Murray, Brett P. Monia, Shuling Guo
-
Publication number: 20190071678Abstract: Provided herein are methods, compounds, and compositions for reducing expression of DYRKIB in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease or disorder in an individual in need.Type: ApplicationFiled: March 16, 2017Publication date: March 7, 2019Applicant: Ionis Pharmaceuticals, Inc.Inventors: Brett P. Monia, Shuling Guo, Susan F. Murray
-
Publication number: 20180169131Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.Type: ApplicationFiled: February 26, 2016Publication date: June 21, 2018Applicant: Ionis Pharmaceuticals, Inc.Inventors: Susan F. MURRAY, Punit P. SETH, Michael L. McCALEB, Susan M. FREIER, Priyam SINGH
-
Patent number: 8158598Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPR.alpha. in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of airway hyperresponsiveness and pulmonary inflammation by administration of antisense compounds targeted to PTPR.alpha.Type: GrantFiled: May 7, 2007Date of Patent: April 17, 2012Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Susan F. Murray
-
Publication number: 20100022619Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPR.alpha. in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of airway hyperresponsiveness and pulmonary inflammation by administration of antisense compounds targeted to PTPR.alpha.Type: ApplicationFiled: May 7, 2007Publication date: January 28, 2010Applicant: ISIS PHARMACEUTICALS, INC.Inventors: Sanjay Bhanot, Susan F. Murray
-
Publication number: 20090209625Abstract: Disclosed herein are compounds, compositions, and methods for modulating the expression of ChREBP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and conditions.Type: ApplicationFiled: May 23, 2007Publication date: August 20, 2009Inventors: Sanjay Bhanot, Kenneth W. Dobie, Susan F. Murray
-
Publication number: 20030212020Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Macrophage migration inhibitory factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Macrophage migration inhibitory factor. Methods of using these compounds for modulation of Macrophage migration inhibitory factor expression and for treatment of diseases associated with expression of Macrophage migration inhibitory factor are provided.Type: ApplicationFiled: October 23, 2002Publication date: November 13, 2003Inventors: Susan F Murray, Lex M Cowsert, Jacqueline Wyatt
-
Patent number: 6436909Abstract: Compositions and methods are provided for modulating the expression of TGF-&bgr;. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TGF-&bgr; are preferred. Methods of using these compounds for modulation of TGF-&bgr; expression and for treatment of diseases associated with expression of TGF-&bgr; are also provided. Methods of sensitizing cells to apoptotic stimuli are also provided.Type: GrantFiled: September 14, 2000Date of Patent: August 20, 2002Assignee: ISIS Pharmaceuticals, Inc.Inventors: Nicholas M. Dean, Susan F. Murray